​

Adial Pharmaceuticals Stock (NASDAQ:ADIL)

OwnershipFinancialsChart
Adial Pharmaceuticals by TradingView

Previous Close

$2.16

52W Range

$1.31 - $19.00

50D Avg

$1.82

200D Avg

$5.23

Market Cap

$2.86M

Avg Vol (3M)

$445.16K

Beta

1.47

Div Yield

-

ADIL Company Profile

Adial Pharmaceuticals, Inc. is a biopharmaceutical enterprise operating at the clinical stage, dedicated to researching and developing innovative therapeutic options for the management and prevention of addiction and associated disorders. Its primary investigational compound, AD04, functions as a selective serotonin-3 antagonist and is currently undergoing pivotal Phase III clinical trials for the treatment of alcohol use disorder. Beyond this flagship product, the company is also exploring drug candidates aimed at providing non-opioid pain relief and addressing a range of other medical conditions. Established in 2010, Adial Pharmaceuticals, Inc. is headquartered in Charlottesville, Virginia.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

5

IPO Date

Jul 27, 2018

Website

ADIL Performance

ADIL Financial Summary

Dec 25Dec 24Dec 23
Revenue---
Operating Income$-7.80M$-8.28M$-6.89M
Net Income$-7.98M$-13.20M$-7.00M
EBITDA$-7.80M$-8.28M$-7.00M
Basic EPS$-11.93$-17.75$-136.00
Diluted EPS$-11.93$-17.75$-136.00

Fiscal year ends in Dec 25 | Currency in USD

Peer Comparison

TickerCompany
CELZCreative Medical Technology Holdings, Inc.
HCWBHCW Biologics Inc.
NRSNNeuroSense Therapeutics Ltd.
ACXPAcurx Pharmaceuticals, Inc.
KPRXKiora Pharmaceuticals, Inc.
BCLIBrainstorm Cell Therapeutics Inc.
APREAprea Therapeutics, Inc.
BCDABioCardia, Inc.
CDIOCardio Diagnostics Holdings, Inc.